Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Molecular Mechanisms6 items
Investigating the oncogenic role of aberrant EZH2 in hepatoblastoma
Read →
Hepatoblastoma (HB) is the most common pediatric liver malignancy. However, its cellular origin and molecular drivers remain poorly defined. Using single-nuclear RNA sequencing (snRNA-seq), we identified a proliferative, hepatocyte-derived
article · Oct 2026
Oncogenic Role of Aberrant EZH2 in Hepatoblastoma.
Read →
Hepatoblastoma (HB) is the most common pediatric liver malignancy. However, its cellular origin and molecular drivers remain poorly defined. Using single-nuclear RNA sequencing (snRNA-seq), we identified a proliferative, hepatocyte-derived
article · Oct 2026
β-Catenin-Cohesin Ring-CEGRs/ALCDs Axis Activation Contributes to the Development of Hepatoblastoma and Fibrolamellar HCC
Read →
Unlabelled: The pediatric and adolescent liver cancers, hepatoblastoma (HBL) and fibrolamellar hepatocellular carcinoma (FLC), respectively, are dangerous diseases requiring aggressive surgery, when feasible, and nontargeted toxic chemother
article · Oct 2026
Primitive Hepatoblasts Driving Early Liver Development
Read →
The embryonic development of the liver is initiated by the emergence of hepatoblasts, originating from the ventral foregut endoderm adjacent to the heart. Here, we identify and characterize a previously unrecognized population of early hepa
article · Oct 2026
EZH2 is a key component of hepatoblastoma tumor cell growth.
Read →
Enhancer of zeste homolog 2 (EZH2) catalyzes the trimethylation of histone H3 at lysine 27 via the polycomb recessive complex 2 (PRC2) and plays a time-specific role in normal fetal liver development. EZH2 is overexpressed in hepatoblastoma
article · Oct 2026
Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma
Read →
Hepatoblastoma (HB) is the most common primary liver malignancy of childhood, and molecular investigations are limited and effective treatment options for chemoresistant disease are lacking. There is a knowledge gap in the investigation of
article · Oct 2026
Cellular Origins and Heterogeneity1 item
Cellular origin and molecular mechanisms of lung metastases in patients with aggressive hepatoblastoma
Read →
Background And Aims: Lung metastases are the most threatening signs for patients with aggressive hepatoblastoma (HBL). Despite intensive studies, the cellular origin and molecular mechanisms of lung metastases in patients with aggressive HB
article · Oct 2026
Metastatic Mechanisms1 item
A developmentally prometastatic niche to hepatoblastoma in neonatal liver mediated by the Cxcl1/Cxcr2 axis
Read →
We found that various HB cell lines including HepG2 cells were consistently and considerably more tumorigenic and metastatic in the P5Tx model than in the P60Tx models. Sc-RNAseq of the P5Tx and P60Tx HepG2 models revealed that the P5Tx tum
article · Oct 2026
Resection Techniques3 items
Surgical management of liver tumors
Read →
Two percent of pediatric malignancies arise primarily in the liver; roughly 60% of these cancers are hepatoblastoma (HB). Despite the rarity of these cases, international collaborative efforts have led to the consistent histological classif
article · Oct 2026
Surgical management of locally-advanced and metastatic hepatoblastoma
Read →
Advanced stage hepatoblastoma, including both locally advanced primary tumors as well as metastatic disease, poses unique clinical challenges. Despite substantial advances in chemotherapeutics, surgical extirpation remains the mainstay of c
article · Oct 2026
Critical elements of pediatric liver cancer surgery
Read →
The appropriate management of pediatric liver malignancies, primarily hepatoblastoma and hepatocellular carcinoma, requires an in depth understanding of contemporary preoperative risk stratification, experience with advanced hepatobiliary s
article · Oct 2026
Fluorescence-Guided Surgery3 items
Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma
Read →
Background: Hepatoblastoma is the most common primary pediatric liver malignancy. Indocyanine green (ICG) has been described as an adjunct to resection in small series. Its utility remains undefined in larger cohorts. Methods: Records for 2
article · Oct 2026
Evolving applications of fluorescence guided surgery in pediatric surgical oncology: A practical guide for surgeons
Read →
Fluorescence-guided surgery (FGS) is an increasingly available and popular method of visual field augmentation. The basic premise of FGS entails injection of fluorescent indocyanine green (ICG) and subsequent detection with a near-infrared
article · Oct 2026
Indocyanine Green Fluorescence for Intraoperative Tumor Identification During Resection of Pediatric and Adolescent Intra-Abdominal Malignancy: A Prospective Multi-Institutional Observational Study
Read →
Background: Real-time intraoperative discrimination of malignant tissue during pediatric solid-tumor resection is limited, constraining margin optimization; the use of indocyanine green (ICG) fluorescence in this population remains incomple
article · Oct 2026
Liver Transplantation for Hepatoblastoma2 items
Quality of Life Outcomes for Patients Who Underwent Conventional Resection and Liver Transplantation for Locally Advanced Hepatoblastoma
Read →
Hepatoblastoma is the most common malignant liver tumor of childhood, with liver transplant and extended resection used as surgical treatments for locally advanced tumors. Although each approach has well-described post-operative complicatio
article · Oct 2026
Hepatoblastoma-The Evolution of Biology, Surgery, and Transplantation
Read →
The most common primary malignant liver tumor of childhood, hepatoblastoma has increased in incidence over the last 30 years, but little is still known about its pathogenesis. Discoveries in molecular biology provide clues but have yet to d
article · Oct 2026
Chemotherapy for Relapsed Disease1 item
Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
Read →
Background: Hepatoblastoma (HB) is the most common liver malignancy in children. There is no standard of care for management of relapsed/refractory HB (rrHB) and reports in the literature are limited. Objective: To describe presenting featu
article · Oct 2026
Novel Therapeutic Targets2 items
Inhibition of Histone Deacetylase Activity Increases Cisplatin Efficacy to Eliminate Metastatic Cells in Pediatric Liver Cancers
Read →
Unlabelled: The pediatric liver cancers, hepatoblastoma and hepatocellular carcinoma, are dangerous cancers which often spread to the lungs. Although treatments with cisplatin significantly improve outcomes, cisplatin may not eliminate meta
article · Oct 2026
Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models
Read →
Background And Aims: Hepatoblastoma (HBL) is a devastating pediatric liver cancer with multiple treatment options, but it ultimately requires surgery for a cure. The most malicious form of HBL is a chemo-resistant aggressive tumor that is c
article · Oct 2026
Utilization of Indocyanine Green for Augmentation of Pulmonary Metastases Resection in Pediatric, Adolescent, and Young Adult Sarcoma Patients
Read →
Background: Complete pulmonary metastasectomy is central to curative-intent therapy for sarcoma, but lesion localization can be challenging. Indocyanine green (ICG) near-infrared fluorescence offers real-time intraoperative guidance, though
article · Oct 2026
Summaries and takeaways+ Show
Summary of this collection+ Show
Key points+ Show
Featured picks for families are being prepared — the summaries above are written for you.
Takeaways+ Show
The doctors in this collection+ Show
All expert statements+ Show
Expert statements from the recordings in this collection.
What's new+ Show
